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ABSTRACT
Murine neural stem cells (mNSCs), either naive or
genetically modiﬁed to express supranormal levels of b-
galactocerebrosidase (GALC), were transplanted into the
brain of Twitcher mice, a murine model of globoid cell
leukodystrophy, a severe sphingolipidosis. Cells engrafted
long-term into the host cytoarchitecture, producing
functional GALC. Levels of enzyme activity in brain and
spinal cord tissues were enhanced when GALC-
overexpressing NSC were used. Enzymatic correction cor-
related with reduced tissue storage, decreased activation
of astroglia and microglia, delayed onset of symptoms,
and longer lifespan. Mechanisms underlying the thera-
peutic effect of mNSC included widespread enzyme dis-
tribution, cross-correction of host cells, anti-inﬂammatory
activity, and neuroprotection. Similar cell engraftment
and metabolic correction were reproduced using human
NSC. Thus, NSC gene therapy rapidly reconstitutes
sustained and long-lasting enzyme activity in central
nervous system tissues. Combining this approach with
treatments targeting the systemic disease associated with
leukodystrophies may provide signiﬁcant therapeutic
beneﬁt. STEM CELLS 2011;29:1559–1571
Disclosure of potential conﬂicts of interest is found at the end of this article.
INTRODUCTION
Globoid cell leukodystrophy (GLD or Krabbe disease) is a
monogenic lysosomal storage disorder (LSD) [1] caused by the
deﬁciency of b-galactocerebrosidase protein (GALC) [2]. The
abnormal accumulation of glycosphingolipids within lysosomes
is considered to be the critical pathogenetic mechanism leading
to oligodendrocyte and Schwann cell death throughout the cen-
tral nervous system (CNS) and peripheral nervous system
(PNS) [2, 3]. The widespread demyelination and neurodegener-
ation are worsened by extensive neuroinﬂammation, a hallmark
that characterizes these and other LSD [1]. The most common
phenotype of GLD is the rapidly progressive early infantile
form, which manifests within the ﬁrst 6 months of life and is
characterized by severe neuro-developmental delay, progressive
motor dysfunction, and early death [4].
A severe hurdle to the treatment of GLD is the inability
to circumvent the blood brain barrier to deliver effective lev-
els of therapeutic enzyme to CNS tissues. Hematopoietic cell
transplant (HCT) using bone marrow and umbilical cord
blood cells from healthy donors have the potential to deliver
functional enzyme to the CNS and PNS by macrophage/
microglia replacement with donor-derived cells [5]. The out-
come of these approaches in LSD patients mainly depends on
the rapidity of progression, on the level of CNS involvement
characterizing the diseases themselves and on the extent of
enzymatic reconstitution achieved in relevant target tissues [6,
7]. Little is known regarding the kinetics post-transplant of
microglia reconstitution in the human CNS. In mice this pro-
cess might require up to 6 months, according to the myeloa-
blative regimen used and the underlying disease [8]. A slow
microglial turnover might preclude obtaining sufﬁcient levels
of corrective enzyme early in postnatal CNS development,
which is critical for myelination and for the correct develop-
ment of CNS connections. This might account for the lack of
deﬁnitive treatment by conventional HCT approach in infan-
tile and early juvenil Krabbe patients [6, 9, 10], in which
white matter tracts are severely compromised already at birth
[11]. In this perspective, approaches ensuring fast, sustained
and widespread enzymatic activity in CNS tissues before the
onset of symptoms or, at least, at the very early stages of the
diseases, might be of relevance to counteract/prevent irrevers-
ible CNS damage.
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tation of enzyme-producing cells [13] might achieve this goal.
In the latter approach, the therapeutic plasticity of neural stem
cells (NSC) might be exploited [14, 15]. NSC [16–18] pro-
mote donor-to-recipient cross correction via enzyme secre-
tion-recapture [19], but can also mediate cell replacement
[20], cell rescue through trophic support [21–23] and other
mechanisms such as immunomodulation [24, 25] and neuro-
protection [21, 26, 27]. Thus, the peculiar NSC biology,
coupled to the secretion of functional GALC may have an
impact on the global neuropathology that characterizes GLD
and similar neurodegenerative LSD [21, 27–30].
Previous studies have tested NSC-based approaches in the
Twitcher mouse, using murine NSC (mNSC) and human NSC
(hNSC) [31–33], an immortalized NSC clone [32, 33] or a
transformed astrocytic progenitor cell line [34]. Overall, these
studies indicated that NSC/progenitor cell types engraft in the
Twitcher brain and secrete the GALC enzyme, providing ther-
apeutic beneﬁt, although no deﬁnitive cure. However, impor-
tant issues such as the long-term survival of NSC in the toxic
Twitcher environment, the efﬁcacy of NSC transplants in
counteracting tissue damage and inﬂammation in widespread
CNS regions and the potential advantage of enzyme overex-
pression in donor cells [31, 33] to achieve therapeutic beneﬁt,
still remained controversial. In addition, the use of trans-
formed cell lines, which in one case resulted in the formation
of brain tumors [34] undermined the relevance of some of
these studies.
The goal of our study was to assess the therapeutic poten-
tial of an ex vivo NSC gene therapy approach in Twi mice.
We comprehensively modeled the engraftment, migration, and
differentiation of somatic NSC after neonatal intracerebroven-
tricular transplantation. We ﬁrst used syngenic mNSC isolated
and cultured from the postnatal brain subventricular zone
(SVZ) [17, 35], either naive or genetically modiﬁed to express
supraphysiological levels of GALC. NSC rapidly engrafted,
migrated and stably expressed the enzyme, which was widely
distributed through the cerebrospinal ﬂuid (CSF) ﬂow to reach
the whole brain and the spinal cord (SC). Supraphysiological
levels of GALC in donor cells resulted in enhanced metabolic
reconstitution of host CNS tissue, which was mediated by
cross-correction, the mechanism by which secreted lysosomal
enzymes are uptaken by neighboring cells. Enzymatic correc-
tion correlated with reduction of tissue storage, decrease of
activated astroglia and microglia, modulation of inﬂammation,
and improved survival. These promising therapeutic beneﬁts
were reproduced using hNSC, which showed similar pattern
of cell engraftment, distribution, and metabolic reconstitution.
MATERIALS AND METHODS
Mouse Strains
Twitcher mice bear a spontaneous point mutation resulting in a
premature stop codon and no residual GALC activity [36]. FVB/
Twi mice were generated in our animal research facility by
breeding heterozygous Twi (þ/ ) C57BL6 mice (Jacson Labora-
tories, Bar Harbor, Maine) with wild-type (WT) (þ/þ) Friend
leukemia virus B (FVB) mice. FVB/Twicher mice (from hereon
called Twi mice) show a slower progressive form of the disease
than the canonical Twicher mice and have more numerous litters.
Tremors develop at around postnatal day 21 (PND21), and pro-
gress to severe resting tremor, weight loss, paralysis and wasting
of hind legs. At 40 days of age, the PNS is severely demyeli-
nated, while CNS tissues show a milder and patchy demyelin-
ation. Death occurs within 45–50 days of age. Age-matched
Twiþ/þ littermates were used as wild-type controls for Twi / 
mice in all the experimental conditions.
Metachromatic leukodystrophy (MLD) mice used to isolate
mNSC were described previously [19]. Mouse colonies were
maintained in the animal facility of the Fondazione San Raffaele
del Monte Tabor, Milano, Italy. Procedures were performed
according to the protocols approved by the Animal Care and Use
Committee of the Fondazione San Raffaele del Monte Tabor
(IACUC #314 and #420).
Vector Production
The bidirectional (bd) lentiviral vectors (LV) used in this study
were used previously and described [19, 37]. The control (CTRL)
vector encodes for green ﬂuorescent protein (GFP) and the trun-
cated form of the low afﬁnity nerve growth factor receptor
(bdLV.DNGFR.GFP, referred to as bdLV.CTRL); the therapeutic
vector encodes for green ﬂuorescent protein and for the murine
GALC cDNA C-terminally tagged with the human inﬂuenza he-
magglutinin epitope (HA) (bdLV.GALC-HA.GFP, referred to as
bdLV.GALC). Monocistronic LV encoding for the human arylsul-
fatase A (ARSA) cDNA were described previously [8, 38].
Reagents, detailed cloning procedures and sequence information
are available upon request. See Supporting Information Experi-
mental Procedures for details on LV preparation.
NSC Cultures and LV Transduction
Murine NSC and hNSC cultures were established and expanded
in serum-free medium (Dulbecco’s modiﬁed Eagle’s medium/F12
1:1 vol:vol containing insulin, apo-transferrin, putrescine, and
progesterone) containing ﬁbroblast growth factor-2 (FGF2) and
epidermal growth factor (EGF) (10 and 20 ng/ml, respectively;
Peprotech, Rocky Hill, NY) (growth medium), according to the
neurosphere assay [17]. Long-term proliferation, self-renewal, and
multipotency were routinely assessed by functional assays [35,
39]. LV transduction was performed on serially subcultured NSC
(passages 5–10 and passages 18–25 for mNSC and hNSC, respec-
tively). See Supporting Information Experimental Procedures for
details on NSC isolation, propagation, and transduction.
Cross-Correction Experiments
WT untransduced (UT) or gene-corrected Twi mNSC were differ-
entiated and used as the source of secreted enzyme (donor cells),
as described previously [19]. UT-Twi and MLD NSC cultures
(acceptor cells), at the same stage of differentiation as donor
cells, were exposed to the supernatant conditioned by donor cells
in the presence or absence of mannose-6-phosphate (M6P; 5 mM)
for the last 72 hours of culture. After a 24-hour washout with
fresh medium, donor cells, acceptor cells, and their supernatants
were collected and analyzed for enzyme activity.
Transplantation
LV-transduced neurosphere bulk cultures (3–10 subculturing pas-
sages post-transduction, corresponding to 15–40 days in culture)
were enzimatically dissociated (Accumax, Millipore, Temecula,
CA, 3 minutes at 37 C) and plated in growth medium. Cells were
collected 48 hours later, centrifuged, mildly mechanically dissoci-
ated, counted by Trypan Blue exclusion (viability >90%), and
resuspended (2.5   10
5 cell/ll) in PBS þ 0.1% DNase (Sigma,
St. Louis, MO). Cells were kept in ice and used within 1 hour.
Cell viability assessed at the end of the transplantation procedure
was >80%. Newborn mice (PND2) were used as recipients. Ani-
mal heads were trans-illuminated to identify the lateral ventricles
and NSC suspensions were rapidly injected (1 or 2 ll/injection
site; bilateral) through trans-cutaneous insertion of the tip of a
hand-drawn glass capillary without exposing the skull. Coordi-
nates for ventricular injections were determinated in pilot dye
injection experiments. The procedure takes less than 5 minutes
for each mouse, then neonates are immediately returned to paren-
tal cures. The overall survival of injected mice was around 90%.
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mNSCs and six mice with hNSCs). A group of untreated Twi (n
¼ 62) and WT littermates (n ¼ 23) were included as controls.
Details on the experimental groups are available in Supporting In-
formation Table 2.
Tissue Processing
Animals were euthanized at PND7 and PND40. A group of trans-
planted animals was allowed to live until terminal stage (body
weight <80% than age-matched WT mice or inability to eat and
drink) to monitor survival. Tissues to be used for GALC activity
measurment and for mRNA proﬁling were collected following
perfusion of animals with saline, to remove contaminating blood.
Brains were cut in two hemispheres and the telencephalon was
separated from the cerebellum and pons. SC was collected as a
whole. Tissues were either quickly frozen in liquid nitrogen or
immediately processed to obtain tissue extracts. Cerebrospinal
ﬂuid (CSF) was collected from the cysterna magna immediately
prior to euthanasia using a hand-drawn glass capillary.
A group of mice were intracardially perfused via the descend-
ing aorta (under deep anesthesia) with 0.9% NaCl followed by
4% paraformaldheyde (PFA) in phosphate buffer solution (PBS).
Brains and SC tissues were collected and equilibrated for 24
hours in 4% PFA in PBS, washed in PBSþNaN3, and then
included in 4% agarose. Serial coronal vibratome-cut sections
(six series, 40 lm thick) were processed for histology and immu-
noﬂuorescence analyses.
Immunohistochemistry, Immunoﬂuorescence,
and Histopathology
Immunoﬂuorescence and histochemistry were performed on free-
ﬂoating vibratome sections as described previously [19]. See Sup-
porting Information Experimental Procedures for detailed proto-
cols and Supporting Information Table 1 for the list of antibodies
used.
Cell Counts and Image Acquisition
The number of engrafted cells was assessed in 40 lm thick coro-
nal brain sections (15–18 sections per mice, corresponding to one
out of six series) using anti-green ﬂuorescence (GFP) antibody,
and expressed as the number of cells per section. Details on cell
counts and image acquisition have been described previously [19]
and are summarized in Supporting Information Experimental
Procedures.
Determination of Enzyme Activity
GALC and arylsulfatase A (ARSA) activity were measured
according to previously described assays [40–42]. See Supporting
Information Experimental Procedures for detailed protocols
regarding the preparation of brain and cell extracts. S300 gel ﬁl-
tration chromatography was performed as described previously
[19].
Gait Analyses
Walking ability of PND40 mice was measured by applying food
coloring to paws and allowing mice to walk on graph papers.
Footprints from individual mice were collected and
photographed.
Statistics
Cell counts, enzyme activity, vector copy number (VCN) values,
and data obtained following the quantiﬁcation of immunopositive
area by the ImageJ software were analyzed with Graph Pad Prism
version 5.0a for Macintosh and expressed as the mean 6 SEM.
Unpaired Student’s t test, Mann-Whitney test, one- or two-way
analysis of variance (ANOVA) followed by Bonferroni, or Dun-
nett’s posttests were used when appropriate (statistical signiﬁ-
cance: p < .05). Log-rank test was used to compare Kaplan-
Meyer survival curves. The number of samples/mice and the sta-
tistical test used are indicated in the legends to each ﬁgure.
RESULTS
Expression, Secretion, and Recapture of
the GALC Enzyme in mNSC Cultures
We transduced WT and GALC-deﬁcient mNSC with a bidir-
ectional lentiviral vector (bdLV) expressing the murine
GALC and the reporter protein GFP (bdLV.GALC) applying
previously optimized conditions [19]. This resulted in high
transduction efﬁciency (70%–90% of GFPþ cells in the neu-
rosphere bulk culture assessed by ﬂuorescence activated cell
sorting (FACS) analysis; vector copy number-VCN- ranging
from 3 to 15), lysosomal localization of the transgenic GALC
(Supporting Information Fig. 1A) and supranormal enzyme
activity (two- to ﬁvefold the WT levels) (Fig. 1A). Cell pro-
liferation and multipotency of GALC-transduced (t) mNSC
(GALCtNSC) were not impaired as compared with
bdLV.CTRL-transduced and UT WT cells (CTRLtWT and
UT WTNSC) (Supporting Information Fig. 1B–1D). The per-
centage of GFPþ cells in differentiated cultures was the same
as in the neurosphere bulk cultures (70%–90%) and was com-
posed by: %8% neurons (TUJ1þ), %12% oligodendrocytes
(GalCerþ) and %80% astroglial (GFAPþ) cells. These per-
centages were similar to those measured in differentiated cul-
tures of untreated cells [43]. We observed a two to threefold
increase in enzyme activity in the differentiated progeny of
WT and enzyme-overexpressing mNSC (Supporting Informa-
tion Fig. 1E).
Higher enzyme activity in gene-corrected mNSC corre-
lated to higher enzyme activity in the supernatant (Fig. 1B),
likely due to increased enzyme secretion. Lysosomal enzymes
can be secreted in the extracellular milieau and can be recap-
tured by neighboring cells mainly through the mannose-6-
phosphate (M6P) receptor (cross-correction) [44]. Exposure of
enzyme-deﬁcient mNSC progeny (acceptor cells) to the super-
natant of enzyme-overexpressing cells resulted in more efﬁ-
cient cross-correction, as shown by higher intracellular GALC
activity measured in acceptor cells (Fig. 1C). Addition of the
competitive inhibitor mannose-6-phosphate (M6P), which
markedly inhibited ARSA reuptake in ARSA-deﬁcient mNSC
cultures in similar experimental conditions (Supporting Infor-
mation Fig. 2) slightly affected GALC uptake in GALC-deﬁ-
cient mNSC progeny (Fig. 1C). These results indicate that
gene transfer corrects GALC deﬁciency of Twi mNSC and
enhances the extent of cross-correction of nontransduced cells.
They also suggest the occurrence of M6P receptor(R)-inde-
pendent reuptake of GALC in mNSC-derived progeny. We
expected that mNSC may similarly cross-correct enzyme-deﬁ-
cient host cells following transplantation in the CNS of
GALC-deﬁcient mice.
Engraftment and Distribution of mNSC
in the Twi Brain
We evaluated whether mNSC engraft, survive, migrate and
differentiate following transplantation in GALC-deﬁcient Twi
mice, also addressing a potential advantage of enzyme-over-
expressing mNSC on their WT counterpart. Asymptomatic
Twi neonates (PND2) and age-matched WT littermates were
transplanted in the cerebral ventricles with Twi or
WT mNSC, transduced with either bdLV.CTRL
(CTRLtTwiNSC and CTRLtWTNSC, expressing no
activity and physiological GALC activity, respectively) or
Neri, Ricca, di Girolamo et al. 1561
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ing supranormal GALC activity). Details regarding experi-
mental groups are available in Supporting Information Table
2. We used two different CTRLtWTNSC lines (GALC activ-
ity: 30–50 nmol/h/mg) and ﬁve different GALCtNSC lines
(three Twi NSC and 2 WT NSC, four independent transduc-
tion experiments; GALC activity: 200–300 nmol/h/mg).
Mice were examined at PND7 and PND40 to evaluate the
engraftment and fate of transplanted cells, which were
detected using an anti-GFP antibody. Indirect immunoﬂuro-
scence (IF) assay on serial rostrocaudal coronal brain sections
from PND40 brains followed by confocal analysis and three-
dimensional reconstruction (Fig. 2A) showed the presence of
GFPþ cells throughout the forebrain, distributed in the paren-
chyma as well as lining the lateral ventricles (Fig. 2B), with a
preference for subcortical white matter tracts (Fig. 2C; corpus
callosum) and the hippocampus (Fig. 2D). We found compa-
rable numbers (Fig. 2E) and similar distribution (Fig. 2F) of
engrafted cells in Twi mice transplanted with the different
mNSC preparations. The yield of engraftment ranged between
0.15% and 2.6% (the percentages might be slightly underesti-
mated since we transplanted bulk NSC preparations contain-
ing 80%–90% of GFPþ cells). Engrafted cells were found in
a region comprised within 2.0 mm rostral and 3.0 mm caudal
from bregma. Few if any cells were found in the cerebellum,
brainstem, and SC. This pattern of cell engraftment and distri-
bution was similar to that found in PND40 WT mice trans-
planted as newborns with GALCtWTNSC, suggesting that
NSC integrate and survive in the inﬂammatory Twi environ-
ment (Supporting Information Fig. 3A). Importantly, GFPþ
cells were found in transplanted Twi mice as early as 5 days
after transplant (PND7; Supporting Information Fig. 3B), with
a yield of engraftment comparable with that measured in Twi
brains at PND40 and at terminal stage (Supporting Informa-
tion Fig. 3C). A similar yield of engraftment was measured in
brain tissues of PND90 WT mice transplanted at birth with
GALCtWTNSC (Supporting Information Fig. 3C), which
were included as controls to check the long-term survival of
engrafted NSC. Finally, we found similar numbers of
engrafted cells in the brains of Twi mice injected with either
cell dose of 0.5   10
6 (5,208 6 871 cells; n ¼ 18) and 1  
10
6 (5,540 6 799 cells; n ¼ 15), suggesting that the majority
of injected cells are cleared in the CSF and that the egress
from the ventricles is the limiting step for proﬁcient engraft-
ment in the brain parenchyma.
We found expression of the proliferation marker Ki67 and
of the apoptotic marker Cleaved Caspase three in <1% of
GFPþ cells at all the time points analyzed (data not shown).
This led us to exclude massive cell loss following cell
engraftment and suggested initiation of lineage commitment.
Cells engrafted in the periventricular region showed immature
morphology (Fig. 3A; lateral ventricle, lv) while the majority
of the cells engrafted in the hippocampus (Hip; Fig. 3B) and
in white matter tracts (corpus callosum, CC; Fig. 3C–3E)
were morphologically similar to astroglial and oligodendro-
glial cells. We assessed the fate of engrafted NSC in the Twi
microenvironment by indirect IF using antibodies to GFP and
to lineage-speciﬁc markers followed by confocal analysis. We
found variable proportions of engrafted GFPþ cells espressing
markers of astroglia (S100b, 21.96%; glial ﬁbrillary acidic
protein (GFAP), 18.09%; Fig. 3F, 3G; a fraction of cells
coexpressed the two markers, as shown in Supporting Infor-
mation Fig. 4), of oligodendroglia (20,30-cyclic nucleotide 30-
phosphodiesterase, 9.79%; glutathione-S-transferase, 6.25%;
NG2, 19.23%, Fig. 3H–3J and Supporting Information Fig. 5;
OLIG2, 8.82%; adenomatous polyposis coli (APC), 16.21%;
b-tubulin IV, 11.46%; Supporting Information Fig. 5) and of
neuronal committment (doublecortin, 19.05% and poly-sia-
lated neural cell adhesion molecule (PSA-NCAM), 18.57%;
Fig. 3K and Supporting Information Fig. 5). We did not ﬁnd
GFPþ cells expressing markers of mature neurons (neuronal
nuclei, NeuN) or myelinating oligodendrocytes (myelin basic
protein, MBP).
Expression and Activity of the GALC Protein in
CNS Tissues of mNSC-Transplanted Twi Mice
We next examined whether transplanted mNSC could provide
robust levels of the GALC protein to CNS tissues of trans-
planted Twi mice. Indirect IF using a previously validated
antibody to GALC [45] followed by confocal analysis showed
GALC expression in the lysosomal compartment (LAMP-1)
of engrafted (GFPþ) GALCtNSC and of surrounding endoge-
nous (GFP ) cells, suggesting the occurrence of cross-correc-
tion (Fig. 4A). This was further conﬁrmed by detection of
GALC expression using immunohistochemistry (Fig. 4B).
Also, we found GFP- cells with glial and neuronal morpho-
logy expressing GALC activity (detected by a histochemical
Figure 1. Wild-type (WT) and transgenic b-galactocerebrosidase
(GALC) proteins are internalized by enzyme-deﬁcient murine neural
stem cell (mNSC) progeny. (A): Copy number of integrated lentiviral
vector (LV) genome (vector copy number, VCN) and enzyme activity
of wild-type (WT) and GALC-deﬁcient Twi mice mNSC populations,
either untransduced (UT) or transduced using bdLV.GALC and
bdLV.CTRL vectors (3   10
7 transducing units/ml) (n ¼ 7 independ-
ent experiments). (B): Enzyme activity in cells and in supernatant
(Sup) of GALC-overexpressing mNSC-derived differentiated progeny
with respect to untransduced (UT) WT cells. (C): Intracellular GALC
activity in Twi mNSC progeny (Twi treated cells) after cross-correc-
tion with supernatants of WT mNSC or of enzyme-overexpressing
cells, in the presence or absence of free M6P. Data analyzed by Stu-
dent’s t test (B) (n ¼ 5 independent experiments) and one-way analy-
sis of variance (Kruskal-Wallis H test followed by Dunnett’s multiple
comparison test) (C) (n ¼ 3 independent experiments). *, p < .05;
***, p < .001.
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cells as well as in hippocampus and cortex (Fig. 4D, 4E), in
which mNSC engraftment was less relevant. Thus, we pro-
vided conclusive evidence that engrafted mNSC produce and
secrete the GALC protein, which is recaptured and correctly
sorted to lysosomes by endogenous host cells, including neu-
rons (Fig. 4F).
By means of S-300 gel ﬁltration chromatography followed
by a speciﬁc assay for detection of GALC activity [41] we
showed a peak of activity corresponding to the MW of the
native enzyme (600–700kD) in brain (Tel) and SC tissues
derived from mNSC-transplanted Twi mice (Fig. 4G). This
peak is absent in tissues from UT Twi mice [19]. The total
GALC activity was signiﬁcantly increased in Tel, Cb, and SC
tissues of NSC-transplanted Twi mice with respect to UT Twi
controls, reaching consistently higher levels in mice trans-
planted with GALC-overexpressing cells (45%–65% of WT
UT) with respect to mice transplanted with CTRLtWTNSC
(30%–40% of WT UT) (Fig. 4H). This was due to higher
enzyme expression and secretion by engrafted GALC-overex-
pressing cells, as assessed by normalizing the total GALC ac-
tivity for the average number of engrafted NSC in each treat-
ment group (Fig. 4I). No detectable GALC activity was
measured in tissues of UT Twi controls or in Twi mice trans-
planted with CTRLtTwiNSC (Fig. 4H). Brain tissues from
GALCtNSC-treated Twi mice analyzed at PND7, PND40, and
at terminal stage revealed similar levels of GALC activity
(Supporting Information Fig. 3D). This data indicate that
early-engrafted mNSC promptly and stably produce and
secrete the GALC enzyme.
We previously demonstrated widespread distribution of
the GALC enzyme through the CSF ﬂow after direct injection
of bdLV.GALC into the Twi CNS [19]. The presence of
GALC activity in the CSF of mNSC-treated Twi mice at
PND40 (Fig. 4J) conﬁrms this mechanism. The CSF-mediated
distribution of the enzyme might also explain the longer time
required to achieve stable levels of GALC activity in SC tis-
sues as compared with Tel tissues (Supporting Information
Fig. 3D).
Reduction of Storage and Amelioration of CNS
Pathology in mNSC-Treated Twi Mice
The widespread GALC biodistribution observed in mNSC-
transplanted Twi mice encouraged us to study the biological
effect of the metabolic rescue, trying to assess the impact of
GALC-overexpression as compared with expression of physi-
ological GALC levels by donor mNSC. An indicator of the
Figure 2. Engraftment and distribution of murine neural stem cell (mNSC) transplanted into the Twi brain. (A): Three-dimensional reconstruc-
tion of a representative Twi mouse brain transplanted with CTRLtWTNSC. Forebrain, gray; lateral ventricles, light blue; white matter, light yel-
low; engrafted GFPþ cells, green dots. (B–D): GFPþ cells in the forebrain subventricular zone lining the lateral ventricles (asterisks in B), in
the corpus callosum (C) and in the hippocampus (D). Scale bars ¼ 0.5 mm (B–D). (E): Percentage of engraftment in Twi mice injected with
wild-type and Twi mNSC transduced with bdLV.CTRL or bdLV.GALC. Data analyzed by one-way ANOVA (Kruskal-Wallis H test followed by
Dunnett’s multiple comparison test), p ¼ .2. (F): Rostrocaudal distribution of engrafted GFPþ cells (experimental groups as described in E). n ¼
3–12 mice per treatment group. Data analyzed by two-way analysis of variance, p ¼ .1245. Abbreviations: CC, corpus callosum; GFP, green ﬂuo-
rescence protein; Hip, hippocampus; lv, lateral ventricle; SVZ, subventricular zone.
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www.StemCells.comFigure 3. Morphology and lineage speciﬁcation of murine neural stem cells transplanted within the Twi central nervous system. (A–C): Repre-
sentative confocal images showing variable morphology of GALCtTwiNSC green ﬂuorescence protein (GFPþ), engrafted in the forebrain sub-
ventricular zone (SVZ) lining the lateral ventricles (A), in the hippocampus (B), and within or close to white matter tracts (i.e., corpus callosum
[CC]; C). (D, E): GFPþ cells with oligodendroglial (D) and astroglial (E) morphology in white matter tracts. (F–K): Representative confocal
merged pictures showing GFPþ cells expressing the astroglial markers S100b (F; CC) and glial ﬁbrillary acidic protein (GFAP) (G), the oligo-
dendroglial markers CNPase (H; CC), GST-p (I), NG2 (J; SVZ), and the neuronal progenitor marker doublecortin (K; hippocampal region). Yel-
low color represents merged signal. Double-labeled cells are indicated by arrows in (G). Confocal z-stack pictures are shown in (F), (I), and (J).
Scale bars ¼ 250 lm( A–C, shown in A), 25 lm( D, E, shown in D), 60 lm( G, K, shown in K), 10 lm (H). Abbreviations: CNPase, 20,30-
cyclic nucleotide 30-phosphodiesterase; DCX, doublecortin; GFP, green ﬂuorescence protein; GST, glutathione-S-transferase; Hip, hippocampus;
lv, lateral ventricle; NG2, chondroitin sulfate proteoglycan.Figure 4. Expression and activity of the b-galactocerebrosidase (GALC) protein in central nervous system tissues of murine neural stem cell
(mNSC)-transplanted Twi mice. (A): Confocal images (merged picture and single channels of the area highlighted in the inset) following immu-
noﬂuroscence analysis using anti-GALC, anti-LAMP-1 (lysosomal marker), and anti-GFP antibody in NSC-transplanted Twi brains. The GALC
protein is expressed in the lysosomal compartment of GALCtTwiNSC (GFPþ engrafted cells) and GFP-GALCþ cells (putative cross-corrected
cells; arrows). Scale bar ¼ 30 lm. (B): Expression of GALC (brown) in the corpus callosum and the hippocampus of mNSC-treated Twi mice as
well as untreated wild-type (WT) and Twi mice. Scale bar ¼ 500 lm. (C): GALC activity (blue, X-Gal) in WT tissues and in NSC-treated com-
pared with untreated Twi mice. (D, D0): GALC activity (blue) in brain regions close to engrafted GFPþ mNSC (brown) as well as in regions
devoid of engrafted cells (D). (D0): Twi tissues show undetectable blue staining. Choroid plexus and blood vessels in WT and Twi tissues showed
nonspeciﬁc X-Gal staining [42]. (E): GALC activity in engrafted mNSC with immature neuronal morphology. Scale bars ¼ 1m m(C), 500 lm
(D),3 0lm (E). (F): GFPþ engrafted cells and endogenous neurons (NeuN; arrows) expressing the GALC protein. Confocal merged picture and
single channels of the area highlighted in the inset are shown. Scale bar ¼ 20 lm. (G) S-300 Gel chromatography showing a peak of enzyme ac-
tivity in telencephalon (Tel), cerebellum (Cb), and spinal cord (SC) tissues derived from representative untransduced (UT) WT and Twi mice
transplanted with CTRLtWTNSC and GALCtTwiNSC. (H): Schematic representation of brain dissection. GALC activity in Tel, Cb, and SC tis-
sues of Twi mice transplanted with mNSC expressing physiological or supraphysiological GALC levels. n ¼ 12 mice per treatment group except
for CTRLtTwiNSC-transplanted mice, in which n ¼ 2. Data analyzed by two-way analysis of variance (ANOVA) follow by Bonferroni post-tests.
*, p < .05 GALCtNSC versus CTRLtWTNSC. (I): Total GALC activity normalized by the average number of engrafted cells. (J): GALC activ-
ity in the cerebrospinal ﬂuid of WT, mNSC-treated, and untreated Twi mice. Data analyzed by one-way analysis of variance (ANOVA) (Kruskal-
Wallis H test, p ¼ .02) followed by Dunnett’s multiple comparison test, *, p < .05 versus all the other treatment groups. Abbreviations: Cb, cer-
ebellum; CC, corpus callosum; GFP, green ﬂuorescence protein; Hip, hippocampus; SC, spinal cord; Tel, telencephalon.beneﬁt of NSC-mediated enzyme reconstitution is its effect
on the major pathological hallmarks of the Twi brain: (a)
accumulation of multinucleated monocyte/macrophage-derived
globoid cells; (b) microglia activation and astrogliosis, with
concurrent upregulation of proinﬂammatory molecules; (c)
oligodendroglial cell death.
Lectin histochemistry detects galactolipid storage in glo-
boid cells of GLD animal models [46]. We quantiﬁed lectin-
immunopositive area in selected brain regions (Supporting In-
formation Fig. 6) of mNSC-transplanted and nontransplanted
Twi and WT mice. Lectin storage is strongly increased in
CNS tissues of untreated Twi mice compared with age-
matched WT mice (Fig. 5A). A 30%–50% reduction of tissue
storage was detected in the Tel, Cb/Pons and SC of mNSC-
transplanted Twi mice as compared with UT Twi controls,
with a signiﬁcative improvement in the Tel of mice trans-
planted with GALC-overexpressing cells (Fig. 5A).
CD68, Iba-1, and GFAP staining are used to monitor the
presence and the activated state of macrophagic, microglial,
and astroglial cells, respectively. NSC-transplanted Twi mice
showed a signiﬁcant reduction (30%–40%) of CD68þ cells
(Fig. 5B) in regions close to engrafted cells (Tel), thus sug-
gesting NSC-mediated cross-correction and/or immunomodu-
lation. In caudal regions (Cb/Pons and SC), a signiﬁcant
downregulation of CD68 expression was found only in mice
transplanted with GALC-overexpressing mNSC. A signiﬁcant
reduction of Iba-1 expression (Fig. 5C) and normalization of
the cell morphology (insets in Fig. 5C) were found in all the
CNS regions of mNSC-treated Twi mice. Downregulation of
GFAP expression (Fig. 5D) was present in the Tel and, to a
lesser extent, in the Cb/Pons and SC of mNSC-treated Twi
mice.
Twi mice display a mild and patchy demyelination in the
telencephalic white matter (Kluver-Barrera staining; Support-
ing Information Fig. 7A). In addition, fewer glutathione S-
transferase (GST)-pþ cells with the typical oval cytoplasm
and a general disarrangement of these cells are present along
the CC of Twi mice, together with scattered GST-pþ debries,
possibly fragmented myelin and oligodendrocyte processes
(Supporting Information Fig. 7B–7D). The myelin appearance,
the morphology, and the organization of GST-pþ cells in the
CC were ameliorated in mNSC-treated Twi mice with respect
to untreated Twi controls (Supporting Information Fig. 7C,
7D).
As mNSC have an anti-inﬂammatory activity when trans-
planted into a chronic inﬂammatory [47], ischemic [48], or
traumatized CNS environment [49], we sought to assess
whether a similar activity could be displayed also in Twi
Figure 5. Murine neural stem cell (mNSC) transplants reduce galactolipid storage and ameliorate pathology in central nervous system (CNS)
tissues of Twi mice. (A–D): Qualitative (representative pictures from different CNS regions: telencephalon [Tel], cerebellum [Cb]/Pons, and spi-
nal cord [SC]) and quantitative analysis of Lectins (A; Cb), CD68 (B; Tel), Iba-1 (C; Tel), and GFAP (D; Cb) in tissues from mNSC-treated and
untreated wild-type (WT) and Twi mice. Insets in (C) show the normalization toward the WT phenotype of Iba-1þ microglial cells in mNSC-
treated Twi mice. Scale bars ¼ 1m m(A–D). n ¼ 3–5 mice per treatment group, three slices per brain region. Data analyzed by two-way analysis
of variance (ANOVA) followed by Bonferroni post-tests. All groups are signiﬁcantly different from untreated WT in (A) and (B) (p < .001). §,
p < .05 versus WT in (C) and (D);* ,p < .05, **, p < .01, ***, p < .001 versus untreated Twi in (A–D). Abbreviations: GFAP, glial ﬁbrillary
acidic protein.
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at late stages of disease progression [50]. We performed
Syber-green quantitative polymerase chain reaction on mRNA
isolated from the Tel and Cb of mNSC-treated Twi mice at
PND40, as well as from age-matched UT WT and Twi litter-
mates. We checked for several proinﬂammatory chemokines
and cytokines known to be upregulated in the Twi CNS com-
pared with WT CNS [i.e., interleukin (IL)-1b, MIP1-a, tumor
necrosis factor-alfa (TNF-a), and chemokine (C-C motif)
ligand 2 (CCL2)] as well as for molecules that could exert
an anti-inﬂammatory (IL-4 and IL-10) or neuroprotective
effect [brain derived neurotrophic factor (BDNF) and ciliary
neurotrophic factor (CNTF)]. Our results showed that mRNA
levels of the proinﬂammatory cytokine IL-1b, of the mono-
cyte chemoattractant CCL2 and of TNF-a were downregu-
lated in mNSC-transplanted as compared with untreated Twi
mice, both in the Tel (Fig. 6A) and in the Cb (Fig. 6B). Inter-
estingly, IL-10, IL-4, and BDNF mRNA levels were upregu-
lated by mNSC treatment, suggesting an immunomodulatory
and neuroprotective role for mNSC in the Twi environment
(Fig. 6A, 6B) that is better appreciable in the Tel, the region
with the highest density of engrafted cells.
Overall, these data demonstrated that mNSC transplanta-
tion in Twi mice results in clearance of tissue storage and
amelioration of histopathology, also suggesting a positive cor-
relation between therapeutic efﬁcacy and supranormal GALC
expression in donor cells. In addition to or as a consequence
of enzyme secretion, we observe an overall reduction of CNS
inﬂammation and the upregulation of growth factors that
might contribute to counteract tissue damage.
Injection of mNSC Delays the Onset of symptoms,
Prolongs Survival, and Ameliorates Motor
Function of Twi Mice
We next examined whether the partial but signiﬁcant impact
of mNSC transplantation in reducing the major pathologic
hallmarks correlated with functional rescue, assessed as pro-
longed survival, and improved motor function. mNSC-treated
Twi mice showed a delay of 6–7 days in the onset of the
symptoms. The average lifespan (days) of Twi mice trans-
planted with CTRLtWTNSC and with GALCtNSC (either
Twi or WT) was 52.7 6 1.7 (n ¼ 10) and 51.3 6 0.6 (n ¼
28), respectively (p > .05). Both values were signiﬁcantly dif-
ferent from the average lifespan of UT Twi mice (47.6 6 0.7;
n ¼ 54). The survival curves of mNSC-treated differed signif-
icantly from that of UT Twi mice (Fig. 6C). Importantly, a
signiﬁcant increase in cumulative survival was observed
between PND40 and PND50 in the mNSC-treated group (i.e.,
cumulative survival at PND49 was 80.0 6 12.6, 71.4 6 8.5,
and 46.3 6 6.7 for CTRLtWTNSC-treated, GALCtNSC-
treated, and UT Twi mice, respectively; p < .05 NSC-treated
vs. UT Twi; p > .05 CTRLtWTNSC-treated vs. GALCtNSC-
treated).
At PND40, Twi mice display a severe twitching and are
highly compromised in their walking ability, due to almost
complete paralysis of hind limbs (Fig. 6D; UT Twi). The
walking performance was improved in the majority of NSC-
treated mice as compared with UT Twi littermates, with some
mice behaving similar to WT controls (17/25 mice analyzed,
68%; four separate transplantation experiments; footprints of
two representative mice, #1 and #2, are shown; Fig. 6D). No
obvious differences were found between mice transplanted
with CTRLtWTNSC or GALCtNSC. All together these results
indicate that rescue of GALC activity achieved by mNSC
therapy in the brain of Twi mice provides amelioration of
CNS histopathology and results in delayed onset of symp-
toms, improved survival and motor function. However, death
eventually occurs, likely consequent not only to the
inability of NSC treatment to target the PNS but also to the
inadequacy of the GALC activity supply provided by engrafted
NSC (which is stable over time) to counteract the build up of
intracellular storage at the late stages of disease progression,
particularly in the caudal CNS regions that rely exclusively on
GALC transport and cross-correction to achieve metabolic
Figure 6. Transplanted murine neural stem cells (mNSC) decrease
inﬂammation, delay the onset of symptoms, and improve motor function
of Twi mice. (A, B): mRNA expression of inﬂammatory markers in tel-
encephalon (A) and cerebellum (B) tissues from wild-type (WT) and
mNSC-treated mice expressed as fold change over the Twi levels. All
samples were normalized to b-actin content. n ¼ 3–4 mice per treatment
group. Data analyzed by two-way analysis of variance (ANOVA) fol-
lowed by Bonferroni post-tests. *, p < .05, **, p < .01 versus untrans-
duced (UT) Twi. §, p < . 0 5U TW Tv e r s u sU TT w i .(C): Kaplan-Meier
survival curves of NSC-treated and untreated Twi mice. Log-rank (Man-
tel-Cox) test, p ¼ .0061 (GALCtNSC), and p ¼ .0037 (CTRLtWTNSC)
versus untreated Twi. GALCtNSC versus CTRLtWTNSC, p > .05. (D):
Gait analysis performed at postnatal day 40 (footprints: black, front
paws; red, rear paws). Number of mice analyzed: NSC-treated, n ¼ 25 (n
¼ 18 GALCtNSC and n ¼ 7 CTRLtWTNSC); untreated WT, n ¼ 9;
untreated Twi, n ¼ 7. Twi #1 and Twi #2 are representative examples of
GALCtNSC-treated Twi mice.
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detected in the Tel but not in the Cb/Pons of Twi mice trans-
planted with GALC-overexpressing NSC and analyzed at the
terminal stage (Supporting Information Fig. 8).
Engraftment and Enzymatic Correction of
mNSC Are Shared by hNSC
Somatic NSC derived from the human fetal brain and cultured
as neurospheres [39, 51] physiologically produce the GALC
protein, showing levels of enzymatic activity comparable with
that measured in WT mNSC (33.67 6 4.48 nmol/hour/mg;
compare with Fig. 1A). We transplanted hNSC transduced
with bdLV.CTRL in the brain ventricles of newborn Twi
mice. Cell engraftment (Fig. 7A) and distribution (Fig. 7B)
assessed at PND40 were remarkably similar to those
described in mNSC-transplanted Twi mice, suggesting low
immunogenicity of hNSC xenograft. Engrafted hNSC dis-
played immature morphology and immunophenotype (Fig.
7C–7E), the vast majority of them expressing nestin (Fig. 7D,
7E). They produced and secreted the GALC protein, allowing
partial restoration of enzyme activity (20%–25% of WT lev-
els), in Tel and SC tissues of transplanted mice (Fig. 7F).
These results, together with data indicating that efﬁcient LV-
mediated overexpression of GALC (Fig. 7G) is achievable in
hNSC, support the feasibility and therapeutic potential of
hNSC gene therapy for the treatment of GLD.
DISCUSSION
In this study, we showed that intracerebroventricular NSC
transplantation provides rapid, robust, and long-lasting NSC
engraftment and production of the GALC enzyme in CNS
tissues of Twi mice, a severe model of GLD. We obtained
proof of principle for this approach with murine and hNSC.
We clarifyed that several mechanisms (enzyme secretion and
distribution, modulation of inﬂammation, neuroprotection, and
cell replacement) concur to achieve NSC-mediated beneﬁt and
elucidated the impact that supranormal enzyme levels in donor
cell might have on the pathology. Overall, we comprehensively
addressed some signiﬁcant and still controversial issues regard-
ing gene/NSC-based approach to treat GLD, highlighting the
potential advantages of this strategy as well as its drawbacks.
The extent of donor/host cell chimerism required to
achieve therapeutic beneﬁt in diseases characterized by disse-
minated CNS damage, the ideal balance between differentia-
tion and persistence of stem/progenitor cells into the targeted
tissue and the ideal mechanism of tissue repair to foster
(whether it has to be cell replacement or tissue protection) are
key and still unsolved issues. The delivery of NSC in the cer-
ebral ventricles of newborn mice described here allowed a rel-
atively uniform rostrocaudal distribution of the cells, which
rapidly accessed the SVZ, the forebrain white matter tracts
(along which they also migrated) and the hippocampal region,
while the most caudal regions were less effectively engrafted.
In line with previous reports [24, 32], we showed that less
than 3% of the injected NSC (regardless the cell preparation
used) engraft and survive in the host CNS (either Twi or WT,
thus excluding a preferential tropism due to the disease).
Interestingly, doubling the number of injected NSC did not
result in increased engraftment, suggesting the presence of a
tight regulation as regard to the number of exogenous cells
that the host brain can integrate, even if the injection is per-
formed in neonates as compared with adults [24].
Figure 7. Cell engraftment, distribution, and metabolic correction of human neural stem cell (hNSC) in Twi mice. (A): Percentage of hNSC
engraftment. (B): Distribution of engrafted hNSC (n ¼ 3 mice). (C–E): hNSC engrafted in the forebrain periventricular region of Twi brains after
immunoﬂuroscence analysis using antibodies to GFP and to human nestin. Scale bars ¼ 250 lm (shown in E). (F): b-galactocerebrosidase (GALC)
activity in central nervous system tissues (telencephalon and spinal cord) of hNSC-transplanted Twi mice (n ¼ 3). (G): GALC overexpression in
hNSC following bdLV.GALC mediated gene transfer. n ¼ 3 independent experiments. Abbreviations: GFP, green ﬂuorescence protein; SC, spinal
cord; SVZ, subventricular zone; Tel, telencephalon; TU, transforming units; UT, untransduced; VCN, vector copy number; WT, wild-type.
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CNS tissues at the late stages of disease progression has been
proposed as a major cause for the limited survival of NSC
transplanted in early postnatal Twitcher brains, which resulted
in progressive decrease of enzyme expression [31]. The stable
number of engrafted cells that we found throughout the brain
of transplanted Twi mice at PND7, PND40, and even at ter-
minal stage indicates the environment in the Twi brain is per-
missive for the engraftment and long-term survival of NSC,
thus implying that NSC-based strategies could be feasible in
GLD. In addition, we showed that WT or enzyme-overex-
pressing NSC do not have a signiﬁcant advantage in terms of
engraftment and survival over Twi cells, suggesting that
intrinsic NSC resistance to psychosine [33] might not be
strictly related to the levels of GALC expression.
Approximately 50% of long-term engrafted NSC
expressed markers for mature astrocytes, oligodendroglial
cells and neuronal progenitors. The absence of NSC-derived
mature neurons and myelinating oligodendrocytes might im-
plicate that additional cues or additional time are required to
achieve full maturation of these cell types. However, this
apparent lack of terminal differentiation and the propensity of
maintaining an undifferentiated phenotype within the host tis-
sue support recent preclinical data indicating that transplanted
NSC are therapeutic efﬁcacious in models of neurodegenera-
tive diseases via a number of bystander mechanisms alterna-
tive to the expected cell replacement [14, 24, 27, 48, 51, 52].
In line with this view, we showed that NSC behaved not
only as effective pumps for the deﬁcient enzyme but also dis-
played putative immunomodulatory and neuroprotective func-
tions upon transplantation in the Twi brain. The total GALC
activity in the CNS of transplanted Twi mice reached 50%
the WT level, not only in the telencephalon, in which we
found the majority of engrafted cells, but also in the cerebel-
lum and in the SC. Widespread enzyme distribution and
cross-correction underlie the therapeutic activity ensured by
NSC transplantation, as they are for the direct intracerebral
gene delivery approach [12, 13]. Using several complemen-
tary assays, we conclusively demonstrated that the GALC
enzyme secreted by NSC is transported through the CSF and
is recaptured by endogenous cells. Cross-correction is particu-
larly efﬁcient in neurons following direct intracerebral deliv-
ery of LV.GALC and LV.ARSA in mutant mice [19, 38],
likely reﬂecting a prevalent neuronal localization of the
M6PR [53, 54]. Still, the presence of cross-corrected oligo-
dendrocytes and astrocytes in the brain of LV.GALC-treated
Twi mice [19] and the results of in vitro experiments reported
here suggest the occurrence of M6PR-independent uptake of
the GALC enzyme in neural cells. Several molecules and
mechanisms have been implicated in M6PR-independent
transport of most acid hydrolases [44]. Further investigation
on the mechanisms of GALC uptake in neural cells would be
of importance for improving gene/cell therapies aimed to treat
GLD.
NSC-transplanted Twi mice showed decreased brain levels
of mRNA species (IL-1b, TNF-a, MIP-1a) known to be pro-
duced by activated macrophages/microglia and astroglia and
able to promote and sustain inﬂammation in the Twi brain
[50]. Our data do not allow dissecting the contribution of a
by-stander effect of NSC with respect to the activity of the
GALC enzyme they produced. However, the marked down-
regulation of IL-1b and TNF-a in the telencephalon as com-
pared with the cerebellum, the upregulation of anti-inﬂamma-
tory molecules (IL-10) and of neurotrophic factors (BDNF)
detected in CNS tissues of NSC-transplanted Twi mice sug-
gest that, besides providing the missing enzyme, NSC might
have neuroprotective and immunomodulatory functions in the
context of reciprocal donor-host signaling in the Twi
environment.
Our data strongly suggest that clearance of glycolipid stor-
age in macrophages and downregulation of activated micro-
glia and astroglia correlate with the levels of GALC activity
in CNS tissues of transplanted mice. These, in turn, correlate
with levels of GALC activity in donor NSC. While NSC
expressing physiological GALC levels might provide the en-
zymatic activity required to normalize several pathological
hallmarks in the high-density engrafted regions, the presence
of GALC-overexpressing NSC is required to provide thera-
peutically relevant GALC levels in the cerebellum and in the
SC. Thus, similar to what observed in vitro, LV-mediated
GALC overexpression results in more efﬁcient enzyme secre-
tion in the extracellular space and, likely, in higher availabil-
ity of cross-correcting enzyme in regions distant from the site
of preferential NSC engraftment.
The metabolic correction provided by NSC transplants
resulted in a functional beneﬁt in Twi mice. Indeed, NSC-
treated Twi mice in this study showed a signiﬁcant increase
in survival proportions between PND40 and PND50, the pe-
riod in which 80% of untreated Twi mice die, clearly indicat-
ing that NSC treatment delays the onset of symptoms. The
overall improved conditions are further conﬁrmed by the
amelioration of walking ability observed at PND40, the time
at which we assessed histopathology and inﬂammatory
proﬁle.
The gain in survival of NSC-treated Twi mice in this
study was lower than that obtained by conventional HCT [55,
56] or in combined approaches [56, 57] but similar to that
obtained by AAV.GALC-mediated intracerebral gene transfer
[58, 59], intrathecal enzyme replacement therapy (ERT) [60]
and transplantation of neural progenitors [31] or mesenchy-
mal-lineage stem cells [61], the latter sharing with NSC the
immunomodulatory and anti-inﬂammatory activity [62, 63]
but displaying a poor yield of long-term engraftment upon
neonatal intracerebral transplantation in the Twi brain [61,
64]. Overall, the functional amelioration of NSC-treated Twi
mice shown here is moderate if compared with the improve-
ment in pathology and ultimately animals succumb to the
disease.
Also, while the potential therapeutic advantage of above-
normal enzyme expression in donor cells has been demon-
strated for HSC gene therapy in MLD [8], MPS I [65], and
GLD mouse models [66], in this study Twi mice transplanted
with GALC-overexpressing NSC did not show a signiﬁcant
amelioration in terms of survival as compared with Twi mice
transplanted with NSC expressing physiological enzyme lev-
els. Several issues related to the biology of disease and of the
donor cells might be considered to explain these apparent
contradictory results. First, clearance of storage strictly corre-
lates with the availability of functional enzyme in the mutant
cells, but the threshold of enzyme activity required at a single
cell level to achieve therapeutic beneﬁt is not deﬁned. Our
comparative analysis performed on NSC-treated Twi mice at
PND40 and at terminal stage strongly suggests that this
threshold increases during the disease progression. Thus, even
the supply of GALC activity provided by engrafted enzyme-
overexpressing NSC is likely inadequate to counteract the
rapid increase of intracellular storage, particularly in the cau-
dal CNS regions, which are affected earlier during the disease
progression as compared with the forebrain. Second, multiple
mechanisms contribute to create symptomatology in Twi
mice, ultimately determining their survival. In particular, the
severe PNS demyelination, which is not targeted by NSC
transplants, strongly contributes to the sharp decrease in cu-
mulative survival observed in Twi mice, irrespectively of
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that GALC deﬁciency induces a psychosine-dependent neu-
ron-speciﬁc damage before or simultaneously to demyelin-
ation [67–69]. This might further explain the limitation of
CNS-directed gene and cell terapies, including NSC and
HCT-based treatments, to treat GLD.
Several preclinical studies indicate low immunogenicity
and virtually no tumorigenicity of somatic hNSC following
transplantation in the neonatal and adult rodent CNS [21, 27,
70–72]. The low immunogenic potential of hNSC that we
describe here in immunocompetent Twi mice is likely due to
the privileged immunological condition of the neonatal brain
and the capacity of hNSC to crosstalk with the inﬂamed CNS
[14, 51]. These data provide additional rationale to the devel-
opment of allogenic hNSC-based approach, which is currently
the only feasible option in humans [73]. Safe gene transfer [22,
51, 74] and GALC overexpression (our unpublished results)
can be achieved in hNSC. However, the clinical development
of NSC gene therapy poses an additional layer of complication
when compared with NSC therapy alone. Thus, careful preclin-
ical studies in the relevant animal models are required to assess
the long-term safety and the therapeutic advantage of above-
normal enzyme expression in donor hNSC.
CONCLUSION
Future therapeutic intervention for complex diseases like
GLD and similar LSD, particularly for the severe infantile
forms, will likely require multidisciplinary strategy and multi-
faceted approaches. Combination of CNS-directed therapies,
such as intracerebral gene delivery [19, 59] or NSC gene
therapy [33; this study] with therapies targeting the PNS, such
as conventional HCT [7, 10] or novel and more efﬁcient HSC
gene therapy strategies [75] performed in the early PNDs of
life may hope to achieve rapid and sustained levels of the
functional enzyme to the affected tissues in an appropriate
time-window, thus consistently prolonging life of affected
patients.
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